BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
BioNexus Gene Lab statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Medical Laboratories companies for comparison
Valuation
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Market Cap | $3.60M | $1.07B |
| Enterprise Value | $2.37M | $1.35B |
| PS Ratio | 1.15 | 1.63 |
| PB Ratio | 0.46 | 3.19 |
| P/TBV Ratio | 0.46 | 4.88 |
Enterprise value
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| EV / Sales | 0.76 | 1.78 |
Income (trailing twelve months)
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Revenue | $3.13M | $543.94M |
| Gross Profit | $385.89K | $162.51M |
| Operating Income | -$2.56M | -$1.92M |
| Pretax Income | -$2.58M | -$575.82K |
| Net Income | -$2.58M | -$1.32M |
| EBITDA | -$2.56M | -$29.24K |
Margins
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Gross Margin | 12.3% | 32.7% |
| Operating Margin | -81.8% | -4.46% |
| Pretax Margin | -82.4% | 1.47% |
| Profit Margin | -82.4% | -3.18% |
| EBITDA Margin | -81.8% | 2.41% |
| FCF Margin | -27.3% | 3.11% |
Returns
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Return on Equity (ROE) | -33.7% | 0.49% |
| Return on Assets (ROA) | -28.4% | -3.06% |
| Return on Invested Capital (ROIC) | -32.3% | 1.25% |
| Return on Capital Employed (ROCE) | -32.3% | -2.29% |
Growth
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -67.3% | 7.11% |
| Revenue Growth (3Y CAGR) | -12.1% | 10.9% |
| Revenue Growth (5Y CAGR) | -8.20% | 13.2% |
Balance sheet
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.23M | $47.58M |
| Net Cash (Debt) | $1.23M | $217.65K |
| Net Cash Per Share | $0.42 | $0.01 |
| Equity (Book Value) | $7.78M | $189.59M |
| Book Value Per Share | $2.65 | $3.32 |
| Tangible Book Value | $7.78M | $1.72M |
| Working Capital | $4.13M | $29.77M |
Financial position
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Current Ratio | 6.08 | 1.41 |
| Quick Ratio | 1.54 | 0.97 |
Cash flow (trailing twelve months)
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Operating Cash Flow | -$846.57K | $1.28M |
| Capital Expenditures | -$7.04K | -$16.47M |
| Free Cash Flow | -$853.60K | $23.23M |
| FCF Per Share | -$0.29 | $0.37 |
Efficiency
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.83 |
| Inventory Turnover | 2.93 | 11.36 |
| Revenue Per Employee | $521.10K | $218.24K |
| Profits Per Employee | -$429.19K | -$5.96K |
| Employee Count | 6 | 897 |
Dividends and yields
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Earnings Yield | -71.5% | -1.25% |
| FCF Yield | -23.7% | 1.43% |
Shares
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Shares Outstanding | 2,933,440 | 58,609,450 |
| Shares Change (QoQ) | 0.00% | 0.29% |
| Float | 2,416,050 | 34,865,600 |
| Shares Held by Insiders | 17.6% | 16.6% |
| Shares Held by Institutions | 0.49% | 85.9% |
Taxes
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Income Tax | $0 | $671.50K |
Scores
| Measure | BioNexus Gene Lab | Industry median |
|---|---|---|
| Altman Z-Score | 1.07 | 1.98 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from BioNexus Gene Lab's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.